AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8795759 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 28
Study 1637268 — intervention group
Group type: EXPERIMENTAL
Intervention: Advancement of the capsulopalpebral head combined with inferior rectus recession
Number of subjects: 0
Study 1637268 — intervention group
Group type: COMPARATOR
Intervention: Inferior rectus recession alone
Number of subjects: 0
Study 6432887 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV)
Number of subjects: 37
Study 6432887 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluorothymidine (TFT)
Number of subjects: 37
Study 6432887 — intervention group
Group type: COMPARATOR
Intervention: Both ACV and TFT
Number of subjects: 37
Study 31472446 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg po bid
Number of subjects: 40
Study 31472446 — intervention group
Group type: COMPARATOR
Intervention: Placebo bid
Number of subjects: 40
Study 30325687 — intervention group
Group type: EXPERIMENTAL
Intervention: HTP (hyaluronic acid-based topical lubricant)
Number of subjects: 60
Study 30325687 — intervention group
Group type: EXPERIMENTAL
Intervention: HA (hyaluronic acid)
Number of subjects: 60
Study 30325687 — intervention group
Group type: COMPARATOR
Intervention: NaCl (sodium chloride)
Number of subjects: 60
Study 30325687 — intervention group
Group type: EXPERIMENTAL
Intervention: HTP
Number of subjects: 60
Study 30325687 — intervention group
Group type: EXPERIMENTAL
Intervention: HA
Number of subjects: 60
Study 30325687 — intervention group
Group type: COMPARATOR
Intervention: NaCl
Number of subjects: 60
Study 27282490 — intervention group
Group type: EXPERIMENTAL
Intervention: LQNS
Number of subjects: 43
Study 27282490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 27282490 — intervention group
Group type: COMPARATOR
Intervention: LQNS and Placebo
Number of subjects: 43
Study 24575916 — intervention group
Group type: EXPERIMENTAL
Intervention: Video conferencing technology (VCT) for mental health data collection
Number of subjects: 19
Study 24575916 — intervention group
Group type: EXPERIMENTAL
Intervention: Video conferencing technology (VCT) for study assessments
Number of subjects: 19
Study 24575916 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer skills
Number of subjects: 19
Study 24575916 — intervention group
Group type: EXPERIMENTAL
Intervention: VCT in various settings
Number of subjects: 19
Study 22975536 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐blockers
Number of subjects: 28
Study 22975536 — intervention group
Group type: COMPARATOR
Intervention: Methimazole + β‐blockers
Number of subjects: 28
Study 22975536 — intervention group
Group type: COMPARATOR
Intervention: Methimazole without β‐blockers
Number of subjects: 28
Study 20116081 — intervention group
Group type: EXPERIMENTAL
Intervention: CK‐IHC (Cytokeratin immunohistochemistry)
Number of subjects: 107
Study 20116081 — intervention group
Group type: COMPARATOR
Intervention: H&E (Hematoxylin and eosin staining)
Number of subjects: 107
Study 20116081 — intervention group
Group type: EXPERIMENTAL
Intervention: CK‐IHC
Number of subjects: 107
Study 18062059 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week cognitive-behavioral stress management (CBSM) intervention
Number of subjects: 71
Study 18062059 — intervention group
Group type: COMPARATOR
Intervention: Half-day stress management seminar (control condition)
Number of subjects: 71
Study 15857284 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% (twice a day)
Number of subjects: 52
Study 15857284 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 1% (3 times a day)
Number of subjects: 52
Study 12461202 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Number of subjects: 442
Study 12461202 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 442
Study 10614063 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (5 mg)
Number of subjects: 16
Study 10614063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7626872 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic temperature (37 degrees C)
Number of subjects: 200
Study 7626872 — intervention group
Group type: COMPARATOR
Intervention: Tepid temperature (34 degrees C)
Number of subjects: 200
Study 30922259 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-zinc-calcium-vitamin D co-supplementation
Number of subjects: 60
Study 30922259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28181941 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4% sodium bicarbonate
Number of subjects: 307
Study 28181941 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride
Number of subjects: 307
Study 26483224 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (4 mg once a day for 7 days)
Number of subjects: 75
Study 26483224 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine medical treatment only)
Number of subjects: 75
Study 23596782 — intervention group
Group type: EXPERIMENTAL
Intervention: Shugan Jianpi Gusui Recipe (SJGR) administered during the remission phase
Number of subjects: 35
Study 23596782 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with azathioprine alone or no treatment
Number of subjects: 35
Study 21331063 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Resistant (IR) group
Number of subjects: 30
Study 21331063 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 17999153 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 ‐819 TT genotype
Number of subjects: 584
Study 17999153 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 ‐592 AA genotype
Number of subjects: 584
Study 16334719 — intervention group
Group type: EXPERIMENTAL
Intervention: Zishen Tongli Jiaonang (capsules for nourishing the kidney and promoting urination)
Number of subjects: 256
Study 16334719 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics according to drug sensitive tests (control group)
Number of subjects: 256
Study 12903793 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 64
Study 12903793 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain
Number of subjects: 64
Study 12903793 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative day
Number of subjects: 64
Study 12903793 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pulmonary function
Number of subjects: 64
Study 12903793 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical style
Number of subjects: 64
Study 12903793 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pulmonary function
Number of subjects: 64
Study 10369064 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential treatment
Number of subjects: 188
Study 10369064 — intervention group
Group type: COMPARATOR
Intervention: Day treatment
Number of subjects: 188
Study 9157769 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release sodium fluoride (SR-NaF)
Number of subjects: 507
Study 1799898 — intervention group
Group type: EXPERIMENTAL
Intervention: NTTS 10
Number of subjects: 12
Study 1799898 — intervention group
Group type: EXPERIMENTAL
Intervention: NTTS 20
Number of subjects: 12
Study 1799898 — intervention group
Group type: EXPERIMENTAL
Intervention: ISD 40
Number of subjects: 12
Study 1799898 — intervention group
Group type: COMPARATOR
Intervention: PL
Number of subjects: 12
Study 6440446 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (500 micrograms)
Number of subjects: 90
Study 6440446 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (250 micrograms at induction, followed by 250 micrograms prior to surgery)
Number of subjects: 90
Study 6440446 — intervention group
Group type: COMPARATOR
Intervention: Halothane (1.5%)
Number of subjects: 90
Study 6440446 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 90
Study 6440446 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone
Number of subjects: 90
Study 30473262 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental video intervention (60-second video emphasizing ability improves with practice)
Number of subjects: 203
Study 30473262 — intervention group
Group type: COMPARATOR
Intervention: Entity video intervention (60-second video emphasizing ability is fixed)
Number of subjects: 203
Study 30473262 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental article intervention (fabricated journal article emphasizing ability improves with practice)
Number of subjects: 203
Study 30473262 — intervention group
Group type: COMPARATOR
Intervention: Entity article intervention (fabricated journal article emphasizing ability is fixed)
Number of subjects: 203
Study 30452209 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release injectable naltrexone (XR-NTX)
Number of subjects: 0
Study 30452209 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone (BUP-NX)
Number of subjects: 0
Study 26888075 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine (TQ)
Number of subjects: 198
Study 26888075 — intervention group
Group type: COMPARATOR
Intervention: Primaquine (PQ)
Number of subjects: 198
Study 24211507 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable polymer-based biolimus-eluting stents (BP-BES)
Number of subjects: 85490
Study 22159173 — intervention group
Group type: EXPERIMENTAL
Intervention: Autorefraction (AR‐EVA score)
Number of subjects: 456
Study 22159173 — intervention group
Group type: COMPARATOR
Intervention: Manual refraction (MR‐EVA score)
Number of subjects: 456
Study 21180000 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) + rinsing + etching
Number of subjects: 50
Study 21180000 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) + no rinsing + etching
Number of subjects: 50
Study 21180000 — intervention group
Group type: EXPERIMENTAL
Intervention: Etching + Chlorhexidine (CHX) + rinsing
Number of subjects: 50
Study 21180000 — intervention group
Group type: EXPERIMENTAL
Intervention: Etching + Chlorhexidine (CHX) + no rinsing
Number of subjects: 50
Study 21180000 — intervention group
Group type: COMPARATOR
Intervention: Etching only (Control group)
Number of subjects: 50
Study 19015420 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigo naturalis ointment
Number of subjects: 42
Study 19015420 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 42
Study 15785911 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser in situ keratomileusis (LASIK)
Number of subjects: 25
Study 11858973 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II and phase III trials for patients with acute and chronic myeloid or lymphoid leukaemia, myelodysplastic syndromes and myeloma
Number of subjects: 330
Study 10711101 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular daily telephone call reminders
Number of subjects: 34
Study 10711101 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily videotelephone call reminders
Number of subjects: 34
Study 10711101 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 34
Study 10711101 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including both intervention groups)
Number of subjects: 34
Study 7477807 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (10 times the recommended daily dose of 9 vitamins)
Number of subjects: 129
Study 7477807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 2029816 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanic membrane temperatures taken with Thermoscan
Number of subjects: 137
Study 7280486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hydrocortisone
Number of subjects: 12
Study 7280486 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular saline (control)
Number of subjects: 12
Study 30053521 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype LSS belt
Number of subjects: 104
Study 30053521 — intervention group
Group type: COMPARATOR
Intervention: Lumbar support
Number of subjects: 104
Study 29885166 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay technique (Group A)
Number of subjects: 100
Study 29885166 — intervention group
Group type: COMPARATOR
Intervention: Sublay technique (Group B)
Number of subjects: 100
Study 25727335 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse containing 0.05% chlorhexidine, 0.05% cetylpyridinium chloride and 0.14% zinc lactate (CHX‐CPC‐Zn)
Number of subjects: 11
Study 25727335 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse containing 0.05% chlorhexidine, 0.15% triclosan and 0.18% zinc pidolate (CHX‐triclosan‐Zn)
Number of subjects: 11
Study 25727335 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (NaCl 0.9%)
Number of subjects: 11
Study 25727335 — intervention group
Group type: COMPARATOR
Intervention: Mechanical plaque control (MPC)
Number of subjects: 11
Study 24945948 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 0
Study 24945948 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 0
Study 23136958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (n=18) received a narrative in ChiChewa with a power point presentation and discussions.
Number of subjects: 36
Study 23136958 — intervention group
Group type: COMPARATOR
Intervention: Control arm (n=18) received standard informed consent information for the microbicide trial.
Number of subjects: 36
Study 20482476 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking with body weight support
Number of subjects: 126
Study 20482476 — intervention group
Group type: COMPARATOR
Intervention: Overground walking
Number of subjects: 126
Study 18926156 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (XIENCE V Everolimus-Eluting Coronary Stent System)
Number of subjects: 39
Study 16977642 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery with relaxation (GIR) for 12 weeks
Number of subjects: 28
Study 16977642 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 28
Study 12697580 — intervention group
Group type: EXPERIMENTAL
Intervention: Arizona Food Frequency Questionnaire (AFFQ)
Number of subjects: 397
Study 12697580 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐hour dietary recalls
Number of subjects: 397
Study 12697580 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 397
Study 10224846 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1b
Number of subjects: 35
Study 8724065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal glycoprotein conjugate vaccine (primary immunization)
Number of subjects: 60
Study 8724065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (secondary immunization)
Number of subjects: 60
Study 1929247 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate, 1 g plus 250 mg per os every 12 h for 3 days
Number of subjects: 6
Study 1929247 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate, 1 g plus 250 mg per os every 12 h on day 3 only (1-day regimen)
Number of subjects: 6
Study 1929247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6191130 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 27
Study 6191130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 29260952 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05%
Number of subjects: 0
Study 29260952 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone Acetate 1%
Number of subjects: 0
Study 29973284 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose JWYH plus usual care
Number of subjects: 240
Study 29973284 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose JWYH plus usual care
Number of subjects: 240
Study 29973284 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus usual care
Number of subjects: 240
Study 28482202 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-to-left (RL) group practicing with the dominant right leg
Number of subjects: 20
Study 28482202 — intervention group
Group type: COMPARATOR
Intervention: Left-to-right (LR) group practicing with the non-dominant left leg
Number of subjects: 20
Study 26277174 — intervention group
Group type: EXPERIMENTAL
Intervention: Saunders traction device
Number of subjects: 150
Study 26277174 — intervention group
Group type: COMPARATOR
Intervention: HILT laser therapy
Number of subjects: 150
Study 23910428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 1662
Study 20936417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg, twice daily)
Number of subjects: 207
Study 20936417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 19003734 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg vitamin C supplementation
Number of subjects: 244
Study 19003734 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg vitamin C supplementation
Number of subjects: 244
Study 17158417 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-enriched formula (EF)
Number of subjects: 0
Study 17158417 — intervention group
Group type: COMPARATOR
Intervention: Formula for term infants (TF)
Number of subjects: 0
Study 14634735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical aiming device
Number of subjects: 50
Study 14634735 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy based surgical navigation system
Number of subjects: 50
Study 10888996 — intervention group
Group type: EXPERIMENTAL
Intervention: Power-assisted adenoidectomy (PAA)
Number of subjects: 177
Study 10888996 — intervention group
Group type: COMPARATOR
Intervention: Adenoid curette adenoidectomy (ACA)
Number of subjects: 177
Study 9373742 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level white noise stimulation
Number of subjects: 96
Study 9373742 — intervention group
Group type: COMPARATOR
Intervention: Information and relaxation training
Number of subjects: 96
Study 9373742 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus management training (general)
Number of subjects: 96
Study 8460615 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive nutritional supplementation at 25% of normal energy recommendations for 6 months
Number of subjects: 16
Study 8460615 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional supplementation)
Number of subjects: 16
Study 3886142 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (1 mg/day, once daily)
Number of subjects: 40
Study 3886142 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (2.5 mg/day, once daily)
Number of subjects: 40
Study 3886142 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa (763 mg/day, twice daily)
Number of subjects: 40
Study 3886142 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (continued therapy for one year)
Number of subjects: 40
Study 31569012 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 441
Study 31569012 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise (NON-EX)
Number of subjects: 441
Study 29628009 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose aprotinin
Number of subjects: 40
Study 29628009 — intervention group
Group type: COMPARATOR
Intervention: Lower doses of aprotinin
Number of subjects: 40
Study 27538896 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (15 bouts of 30 s at 90%-95% of maximal heart rate)
Number of subjects: 44
Study 27538896 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (40 min at 65%-75% of maximal heart rate)
Number of subjects: 44
Study 26527048 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-Pharmacist Collaboration Intervention
Number of subjects: 625
Study 26527048 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 625
Study 22146999 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 47
Study 22146999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 22146999 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude exposure
Number of subjects: 47
Study 20008640 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutation status
Number of subjects: 3278
Study 20008640 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF mutation status
Number of subjects: 3278
Study 18517077 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fexofenadine (180 mg)
Number of subjects: 18
Study 18517077 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diphenhydramine (50 mg)
Number of subjects: 18
Study 18517077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diphenhydramine (50 mg)
Number of subjects: 18
Study 18517077 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 18
Study 16043675 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone patch 300 microg/d
Number of subjects: 447
Study 16043675 — intervention group
Group type: COMPARATOR
Intervention: Testosterone patch 150 microg/d
Number of subjects: 447
Study 16043675 — intervention group
Group type: COMPARATOR
Intervention: Testosterone patch 450 microg/d
Number of subjects: 447
Study 16043675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study 12427118 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human enzyme, alpha-galactosidase A (r-halalphaGalA), administered IV at 1 mg/kg biweekly for 11 months
Number of subjects: 58
Study 12427118 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human enzyme, alpha-galactosidase A (r-halalphaGalA)
Number of subjects: 58
Study 10072221 — intervention group
Group type: EXPERIMENTAL
Intervention: Le(a‐b‐) phenotype
Number of subjects: 1620
Study 8704837 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic mattress replacement surface 1
Number of subjects: 110
Study 8704837 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic mattress replacement surface 2
Number of subjects: 110
Study 8704837 — intervention group
Group type: EXPERIMENTAL
Intervention: Static foam mattress replacement
Number of subjects: 110
Study 8704837 — intervention group
Group type: COMPARATOR
Intervention: All support surfaces
Number of subjects: 110
Study 8704837 — intervention group
Group type: EXPERIMENTAL
Intervention: Braden Scale score
Number of subjects: 110